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Abstract
Non-alcoholic steatohepatitis (NASH) is growing into global problem, mainly due to 
NASH-induced cirrhosis and hepatocellular carcinoma (HCC), that can develop either 
subsequently to cirrhosis or preceding it. In addition, NASH-induced cirrhosis consti-
tutes a significant fraction of cases diagnosed as cryptogenic cirrhosis. Thus, there is a 
need for deeper understanding of the molecular basis, leading to liver steatosis, then—to 
the associated inflammation seen in NASH, loss of liver architecture and cirrhosis, fol-
lowed or paralleled by carcinogenesis and HCC. Insulin resistance, increased hepatic 
iron level, and certain cytokines, including TNF-α and IL-6 derived from extrahepatic 
adipose tissues, can trigger the chain of events. The imbalance between leptin and adi-
ponectin is important as well. These markers remain important during the whole course 
from NASH through liver cirrhosis to HCC. The molecular pathogenesis substantiates 
treatment: hypertriglyceridemia can be lowered by low calorie diet; mTOR complex 
can become inhibited by physical activity and metformin; cholesterol synthesis, RAF/
MAPK1/ERK and p21 pathway by statins; inflammation by pentoxyfillin, and kinases 
(in HCC) by sorafenib. Bidirectional regulation of telomere attrition, senescence and p21 
pathway, restoration of wild-type p53 activity and regulation of miRNA network repre-
sent attractive future treatment options. Focusing on relevant molecular pathways allows 
deeper understanding of NASH pathogenesis, leading to identification of predictive 
markers and treatment targets.
Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver cirrhosis, 
cryptogenic cirrhosis, hepatocellular carcinoma
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a clinical and pathological entity with features 
that resemble alcohol-induced liver steatosis, but, by the definition, it occurs in patients with 
little or no history of alcohol consumption. NAFLD is subdivided into non-alcoholic fatty 
liver (NAFL) and non-alcoholic steatohepatitis (NASH). It encompasses a histological spec-
trum that ranges from fat accumulation in hepatocytes without concomitant inflammation 
or fibrosis (simple hepatic steatosis, NAFL) to hepatic steatosis with a necroinflammatory 
component (inflammation-induced apoptosis in hepatocytes) that may or may not have asso-
ciated fibrosis. The latter condition, referred to as non-alcoholic steatohepatitis (NASH), can 
lead to NASH-induced liver cirrhosis (Figure 1). In addition, NASH is now recognised as 
the main cause of cryptogenic cirrhosis [1], as sequential association has been demonstrated 
in up to 75% of cryptogenic cirrhosis cases (see also Section 3 for detailed discussion of the 
relationships between NASH and cryptogenic cirrhosis). Liver cirrhosis may further lead to 
hepatocellular carcinoma (HCC), the most common primary liver cancer known for its poor 
clinical outcome and limited therapeutic options. Although previously it was considered that 
risk of HCC is limited to cirrhotic patients [2], a significant fraction of NASH-associated HCC 
develops in liver showing none or mild fibrosis. The association between NAFLD/NASH and 
increased HCC risk is supported by strong epidemiologic evidence.
In the year 2010, the annual incidence of HCC in the population of the USA was at least 
6 per 100,000. The mortality rate was almost identical to the incidence underscoring the seri-
ous prognosis [3]. Patients with NAFLD/NASH are subjected to an increased lifetime risk 
of HCC. In a 16-year follow-up study, the standardised incidence ratio of HCC in patients 
with NAFLD/NASH was 4.4 [4]. In a recent global meta-analysis, the HCC incidence among 
NAFLD patients reached 0.44 (range, 0.29–0.66) per 1000 person-years [5]. The HCC-related 
mortality rates among NAFLD patients range from 0.25 to 2.3% over 8.3 and 13.7 years of 
follow-up, respectively [5, 6]. NAFLD/NASH-associated HCC is believed to be the leading 
cause of obesity-related cancer deaths in middle-aged men in the USA [4]. Consistently, the 
proportion of HCC related to NAFLD/NASH is increasing worldwide and is reported to range 
between 4 and 22% in Western countries [7]. Although the exact burden of HCC associated 
with NAFLD/NASH still remains uncertain, it seems evident that NAFLD and NASH will 
become the most common causative/risk factors for HCC, surpassing viral or alcohol-related 
cirrhosis in the future [7]. In the USA, the number of NAFLD-associated HCC cases is annually 
growing (2004–2009) for 9% [8], while decreased burden of viral hepatitis-induced HCC might 
be expected due to the achievements in antiviral treatment targeting hepatitis C virus [9].
NAFLD is the major hepatic manifestation of obesity and associated metabolic conditions. The 
epidemiology of NAFLD mirrors the recent spread of obesity and diabetes. With increasing 
prevalence of these conditions, NAFLD has become the most common liver disorder in USA 
[10] and other Western industrialised countries, facing high occurrence of the major risk factors 
for NAFLD, namely, central obesity, type 2 diabetes mellitus, dyslipidemia and metabolic syn-
drome [11]. In a recent meta-analysis of 86 studies, comprising 8,515,431 persons from 22 coun-
tries, the global prevalence of NAFLD was 25.24% (95% confidence interval [CI], 22.10–28.65) 
showing the highest occurrence in the Middle East and South America and the lowest in Africa [5]. 
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Thus, 90% of patients suffering from morbid obesity (defined as having body mass index 40 
kg/m2 or higher) and 74% patients affected by diabetes mellitus develop NAFLD. In addition, 
NAFLD has been observed even in non-obese, non-diabetic patients who have increased insu-
lin levels in blood and resistance to insulin action. Consequently, NAFLD affects up to 20–30% 
of adults in Europe and 46% in the USA: a tremendously high prevalence for a condition that 
can cause any significant complications [9, 10].
Figure 1. Progression of NAFLD. Abbreviations: IL, interleukin; TNF, tumour necrosis factor; ROS, reactive oxygen 
species; Fe, accumulation of iron compounds.
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Most patients are diagnosed with NAFLD in their 40s or 50s. Studies vary in regard to the 
gender distribution of NAFLD, with some suggesting that it is more common in women and 
others suggesting more frequent occurrence in men [11, 12].
Since 1998, non-alcoholic fatty liver disease has been considered a condition with a “two-hit” 
course of pathogenesis, first proposed by Day and James [13], describing the role of lipid 
peroxidation in liver injury. The “first hit” is the development of hepatic steatosis. It was 
suggested that hepatic triglyceride accumulation increased the susceptibility of the liver to 
the “second injury hit” by inflammatory cytokines and/or adipokines, mitochondrial dys-
function and elevated oxidative stress that together promote steatohepatitis and fibrosis [14]. 
Alternatively, many factors may act simultaneously leading to the development of NAFLD: 
this hypothesis corresponds to the multihit model proposed by Tilg and Moschen [15].
Experimental and population studies have shown the links between NAFLD/NASH and 
development of HCC. However, the mechanisms by which NASH progresses to HCC are 
only beginning to be elucidated [14]. NASH is the most rapidly growing risk for liver trans-
plantation because of HCC. Wong et al. in their study included 61,868 patients over the period 
2002–2012 and found that the proportion of NASH-related HCC increased from 8.3 to 13.5%, 
an increase of near 63% [16].
This increase is alarming as HCC already is the fifth most frequently diagnosed cancer and 
the second leading oncologic death cause worldwide [17], with increasing incidence and 
mortality rates in Europe [18]. Thus it is crucial to analyse molecular pathways involved 
in NASH-induced cirrhosis and HCC carcinogenesis. Focusing on the molecular events 
involved in pathogenetic chain of events from NASH to liver cirrhosis and HCC would pro-
vide not only better theoretical understanding of liver diseases preceding and following cir-
rhosis but would also allow to recognise predictive markers and treatment targets before 
HCC development.
2. Common pathogenetic mechanisms of NAFLD
Hepatic steatosis or excessive triglyceride accumulation in the liver is a prerequisite to the 
histological diagnosis of NAFLD. Several mechanisms may lead to steatosis, including (1) 
increased fat supply because of high-fat diet or excess lipolysis in adipose tissues, which 
increase free fatty acid (FFA) level; (2) decreased fat export in the form of very low density 
lipoprotein-triglyceride complex, secondary to either reduced synthesis of the relevant pro-
teins or compromised excretion; (3) decreased or impaired β-oxidation of FFA to adenosine 
triphosphate and (4) increased hepatic synthesis of fatty acids through de novo lipogenesis 
[1, 19]. Free fatty acid delivery to the liver accounts for almost two-thirds of its lipid accumula-
tion. De novo lipogenesis therefore only contributes to the accumulation of hepatic fat in case 
of NAFLD [15].
The molecular mechanisms responsible for the accumulation of fat in the liver are complex 
(Figure 2). Certain inflammatory cytokines, particularly those derived from extrahepatic 
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adipose tissues, can trigger this process. Insulin resistance appears to be at the centre for 
the massive metabolic dysregulations that initiate and aggravate hepatic steatosis. At a 
certain point, the simple steatosis transforms to steatohepatitis in about 20–30% of NAFLD 
patients [19]. A major feature in the transition from NAFLD to NASH is the appearance 
of hepatic inflammation [14]. This breakthrough-like process is mediated by the interplay 
of multiple hit factors and is orchestrated by rich network of miRNAs [20]. Currently, a 
number of common pathogenetic mechanisms have been proposed and characterised for 
the transition from simple steatosis to NASH [19]. A summary of these mechanisms is 
shown in Figure 3.
2.1. Inflammation in peripheral adipose tissue
Hypoxia and death of rapidly expanding adipocytes are considered important initiating fac-
tors of adipose tissue inflammation in obesity [19]. During inflammation, typical cytokines 
like tumour necrosis factor (TNF)-α, interleukin (IL)-6 and CC motif chemokine ligand 2 
(CCL2) are secreted by inflammatory cells infiltrating adipose tissue [21]. TNF-α was the first 
pro-inflammatory cytokine detected in adipose tissue. TNF-α and IL-6 are involved in the 
regulation of insulin resistance [19]. TNF-α and IL-6 induce insulin resistance in adipocytes, 
stimulating triglyceride lipolysis and fatty acid release into the circulation. CCL2 recruits 
macrophages to the adipose tissue, resulting in even higher local cytokine production and 
perpetuating the inflammatory cycle [19]. In the liver, increased expression of hepatic IL-6 
correlates with higher degree of insulin resistance in patients with suspected NAFLD [1].
At the same time, extrahepatic adipocytes are compromised in their natural ability to secrete 
adiponectin, an anti-inflammatory adipokine that facilitates the normal partitioning of lipid 
Figure 2. Pathogenesis of liver steatosis. Abbreviations: FFA, free fatty acids; TG, triglycerides; IL, interleukin; TNF, 
tumour necrosis factor; CCL2, CC motif chemokine ligand 2; VLDL, very low density lipoproteins.
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Figure 3. Pathogenesis of non-alcoholic steatohepatitis. Abbreviations: CYPE1, cytochrome CYP2E1; ROS, reactive 
oxygen species; Fe, iron; NF-κB, nuclear factor kappaB; IL, interleukin; TNF, tumour necrosis factor; HSC, hepatic 
stellate cells.
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to adipocytes for storage [19]. Adiponectin is a hormone secreted exclusively by adipose tis-
sue. It has beneficial effects on lipid metabolism. In the liver, adiponectin is considered to 
have insulin-sensitising, anti-fibrogenic and anti-inflammatory properties by acting on hepa-
tocytes, liver stellate cells and hepatic macrophages (Kupffer cells), respectively. Adiponectin 
suppresses the transportation of free fatty acids to the liver as well as gluconeogenesis and 
de novo synthesis of fats but enhances oxidisation of FFAs [21]. The adiponectin-induced sup-
pression of aldehyde oxidase and transforming growth factor has net anti-fibrotic effect [21], 
while decreased release of pro-inflammatory cytokines including TNF-α reduces inflam-
mation [1]. Decreased levels of adiponectin result in loss of these protective metabolic, anti-
fibrotic and anti-inflammatory effects.
Together, these abnormalities accentuate fat loss from adipocytes and promote ectopic fat 
accumulation [19].
2.2. Insulin resistance
Obesity and type 2 diabetes mellitus, both conditions associated with peripheral insulin resis-
tance, are frequently diagnosed in patients affected by non-alcoholic fatty liver disease [12]. 
Evaluating patients suffering from diabetes mellitus, NAFLD was found in 74% of them in 
North American study, 70% in Italian population and 35–56% in Eastern countries. In Mexico, 
prevalence of NASH in diabetics was 18.5%. The prevalence of NAFLD in obese patients is 
57–90% in Western and 10–80% in Eastern populations. NASH is present in 15–20% patients 
affected by obesity. The frequency of NASH is higher in those undergoing bariatric surgery 
and can reach 48–60% in USA men, 20–31% in USA females and up to 80% in Taiwan patients 
[9, 10, 12].
Insulin resistance has also been observed in NASH patients who are not obese and those who 
have normal glucose tolerance [1]; however, not all people with NAFLD have increased insu-
lin resistance. NAFLD also cannot be considered as a cause for insulin resistance but rather 
as a consequence [19].
Resistance to the action of insulin results in important metabolic changes, including the turn-
over of lipids. It is characterised not only by increased circulating insulin levels but also by 
increased hepatic gluconeogenesis, impaired glucose uptake by muscle, enhanced peripheral 
lipolysis, increased triglyceride synthesis and increased hepatic uptake of fatty acids, as well 
as increased release of inflammatory cytokines from peripheral adipose tissues, which are the 
key factors promoting accumulation of liver fat and progression of hepatic steatosis [1, 19].
2.3. Lipotoxicity
The term “lipotoxicity” describes the deleterious effects of excess FFA and ectopic fat accumu-
lation resulting in organ dysfunction and/or cellular death. In obesity, excessive food intake 
combined with high FFA output from insulin-resistant adipose tissue surpasses the storage 
and oxidative capacity of tissues such as skeletal muscle, liver, or pancreatic β-cells [22]. 
Long-chain saturated fatty acids, as well as free cholesterol derived from de novo synthesis 
can be harmful to hepatocytes. Free cholesterol accumulation leads to liver injury through 
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the  activation of intracellular signalling pathways in Kupffer cells, liver stellate cells, and 
hepatocytes [19], ultimately promoting inflammation and fibrosis [23]. FFAs are redirected 
into noxious pathways of nonoxidative metabolism with intracellular accumulation of toxic 
metabolites. It is not TG accumulation per se that is uniquely hazardous, but rather the lipid-
derived metabolites that trigger the development of reactive oxygen species (ROS) and acti-
vation of inflammatory pathways [22], including up-regulation of nuclear factor kappaB, 
production of TNF-α and IL-6 [24], and the subsequent inflammatory reaction in the liver [1].
2.4. Oxidative stress
In the context of increased supply of fatty acids to hepatocytes, oxidative stress can occur. 
It is attributable to the raised levels of reactive oxygen/nitrogen species and lipid peroxida-
tion that are generated during free fatty acid metabolism in microsomes, peroxisomes, and 
mitochondria [19]. NAFLD and NASH-induced oxidative stress is partly regulated through 
cytochrome P450 2E1 (CYP2E1) as it metabolises C10–C20 fatty acids [14] that in turn pro-
duce hepatotoxic free oxygen radical species [1]. Peroxidation of plasma and intracellular 
membranes may cause direct cell necrosis/apoptosis and development of megamitochondria, 
while ROS-induced expression of Fas-ligand on hepatocytes may induce fratricidal cell death 
[19]. Recent studies support the idea that oxidative stress may be a primary cause of liver 
fat accumulation and subsequent liver injury [25], as well as ROS may play a part in fibrosis 
development. Lipid peroxidation and free oxygen radical species can also deplete antioxidant 
stores such as glutathione, vitamin E, beta-carotene, and vitamin C, rendering the liver sus-
ceptible to oxidative injury [1].
2.5. Increased hepatic iron concentration
The degree of liver fibrosis in nonalcoholic steatohepatitis shows correlation with the concen-
tration of iron compounds in the hepatocytes. The underlying mechanism might involve the 
ferric-to-ferrous reduction (switch of trivalent Fe(III) to divalent Fe(II) compounds), resulting 
in simultaneous production of free oxygen radicals [1]. In addition, sinusoidal iron accumu-
lation might also have a pathogenetic role in the progression of chronic liver diseases and 
development of hepatocellular carcinoma [26]. However, at least in Eastern populations, dis-
turbances of iron metabolism are rarely observed in NAFLD patients [12]. In patients without 
iron overload, increased ferritin level in the blood may still be associated with insulin resis-
tance and fatty liver [27].
2.6. MicroRNAs in NAFLD
MicroRNAs are small molecules of non-coding RNA that act as large-scale molecular switches. 
The pathogenetic chain of events in the transition to NAFL, NASH, and liver cirrhosis is richly 
regulated by miRNA network: it has been estimated that approximately 54 miRNAs regu-
late 107 genes involved in the development of NAFLD. The up-regulation of miR-26b and 
down-regulation of miR-26a decrease insulin sensitivity, while lower levels of miR-451 are 
associated with pro-inflammatory background. The up-regulation of miR-155 and miR-107 
promotes fat accumulation in liver cells. Enhanced fibrosis is mediated by miR-21. Assessing 
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patients with NAFLD-associated liver fibrosis, at least 9 miRNAs are expressed in modified 
levels, including higher expression of miR-31, miR-182, miR-183, miR-224, and miR-150 as 
well as down-regulated levels of miR-17, miR-378i, miR-219a, and miR-590. In the progres-
sion of liver fibrosis, the normally high levels of miR-22 and miR-125b are suppressed. The 
miR-29 family showing anti-fibrotic action in many organs is also suppressed [20].
3. NASH-induced liver cirrhosis
Liver cirrhosis develops (Table 1) when simple steatosis progresses to steatohepatitis and 
then fibrosis [11]. The composition of the hepatic fibrosis is similar regardless of the cause of 
injury as it follows the paradigm for wound healing in other tissues, including skin, lung and 
kidney. Fibrosis occurs first in regions of most severe injury over several months to years of 
ongoing tissue damage [23, 28, 29].
Targets Involved cells or molecules Result
Stellate cells Activated stellated cells are 
transformed to proliferating, 
fibrogenic and contractile 
myofibroblasts
Remodelling of the matrix
Macromolecules in the extracellular 
matrix
Collagens: the total collagen content 
increases 3- to 10-fold including an 
increase in fibril-forming collagens 
(i.e., types I, III, and IV) and some 
non-fibril forming collagens (types 
IV and VI).
The extracellular matrix switches 
from the normal low-density 
basement membrane-like matrix to 
the interstitial type
Glycoproteins: fibronectin, laminin, 




decorin, aggrecan, lumican, and 
fibromodulin
Proteoglycans: shift from heparan 
sulphate-containing proteoglycans 
to those containing chondroitin and 
dermatan sulphates
Degradation of extracellular matrix Matrix metalloproteinase 2 Disruption of normal matrix 
facilitates replacement by 
desmoplastic matrixMatrix metalloproteinase 9
Membrane-type metalloproteinase 1 
and/or 2
Stromelysin 1
Table 1. The key structures in the development of liver cirrhosis.
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Cryptogenic cirrhosis is the end stage of a chronic liver disease in which the underlying 
aetiology remains unknown after extensive clinical, serological and pathological evaluation 
[30, 31]. In different studies, 3–30% of liver cirrhosis cases have been attributed to the crypto-
genic group [9]. Naturally, occasionally the diagnosis of cryptogenic cirrhosis is issued just 
due to lack of information despite the definition demanding complete investigation. Studying 
explanted livers of cirrhotic patients undergoing liver transplantation and having preopera-
tive diagnosis of cryptogenic cirrhosis, specific cause was identified in 28.6% of cases. The 
relevant diagnoses included autoimmune hepatitis, sarcoidosis, primary biliary cirrhosis, 
sclerosing cholangitis, congenital hepatic fibrosis and Wilson’s disease [32]. Other data/inves-
tigational methods can yield significant information as well. For instance, a significant frac-
tion of cases initially diagnosed as cryptogenic liver cirrhosis can be associated with occult 
hepatitis B infection [33].
Recent evidence suggests that cryptogenic cirrhosis is strongly associated with development 
of HCC, while in a varying percentage (6.9–50%) of HCC, the underlying aetiology of liver 
disease cannot be determined. In a retrospective study of 641 HCC patients, cryptogenic 
cirrhosis was found in 44 (6.9%) cases, characterised also by more frequent occurrence of 
obesity and diabetes mellitus than in patients having history of chronic viral hepatitis and 
alcohol abuse. Considering the known association between obesity, diabetes and NASH, it 
was hypothesised that NASH is the precursor of cryptogenic cirrhosis and hepatocellular 
carcinoma [34].
At present, there is strong evidence that cryptogenic cirrhosis represents the end state of 
NASH at least in a fraction of patients. First, the progression of fibrosis in NASH is associated 
with gradual loss of fat vacuoles. Thus, the specific morphological changes would be burned 
out when the cirrhosis develops. Second, patients diagnosed with cryptogenic cirrhosis have 
high prevalence of metabolic changes as type 2 diabetes mellitus, obesity, or history of those 
disorders. If the history of preceding diabetes mellitus or obesity or liver biopsy revealing 
NAFLD is considered as the diagnostic criteria, 30–75% of cryptogenic cirrhosis cases can be 
retrospectively associated with NASH [9]. Third, due to growing awareness of the entity of 
NASH-induced cirrhosis, direct evidence has been brought by data obtained in explanted liv-
ers. Cases that were clinically diagnosed as cryptogenic cirrhosis were reclassified as NAFLD 
(either cirrhosis or pre-cirrhotic stage) in 78.6% of cases [12, 35, 36].
In comparison with liver cirrhosis due to other aetiologies, NASH-induced cirrhosis is diag-
nosed in older patients. Higher cardiovascular mortality is observed, in addition to the classic 
complications of liver cirrhosis attributable to portal hypertension and oesophageal variceal 
bleeding, infections and renal failure [9].
In a population-based, large study, carried out in the United Kingdom, the following dis-
tribution of cirrhosis by the cause was found (in patients, diagnosed in 1987–2006): alcohol-
induced, 56.1%; cryptogenic, 20.8%; attributable to viral hepatitis, 12.0%; autoimmune or 
metabolic (i.e., in this study—haemochromatosis or alpha-1-antitrypsin deficiency), 11.0% 
[37]. In a nationwide Danish study regarding 11,605 patients diagnosed with liver cirrhosis in 
1977–1989, 61.7% of cases were alcohol-induced, 2.8%—attributable to primary biliary cirrho-
sis, 14.6%—related to chronic hepatitis (including autoimmune inflammation) and 20.9%—
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non-specified [38]. Regarding the cause of cirrhosis in explanted livers, 48.6% were related to 
chronic viral hepatitis (31.1% to HCV and 15.9% to HBV, 1.6% to HCV and HBV coinfection), 
23.1% to alcohol-induced liver damage and 16.7% to NAFLD [36]. The data on explanted liv-
ers may not reflect the true incidence of NASH-induced cirrhosis as NAFLD patients are less 
likely to receive transplant. The probability to receive liver transplant within 1 year is 40.5% 
in NAFLD, contrasting with 47% for hepatitis C or alcohol-induced cirrhosis. The difference 
is the result of several factors: contraindications due to morbid obesity, comorbidities, older 
physiologic age, impaired renal function as well as slower disease progression [9].
Thus, cryptogenic cirrhosis is a significant burden for health care systems. Patients undergoing 
liver transplantation for cryptogenic cirrhosis are subjected to higher postoperative mortality, 
lower cumulative 5- and 10-year survival and higher rate of chronic rejection [32]. NASH is the 
most rapidly growing indication for simultaneous liver and kidney transplantation. NASH 
and cryptogenic cirrhosis in patients having body mass index greater than 30 kg/m2 constituted 
6.3% in the years 2002–2003 but 19.2% in the years 2010–2011 [39].
As the liver becomes fibrotic, significant changes occur in the extracellular matrix (ECM) 
quantitatively and qualitatively. ECM refers to macromolecules that comprise the scaffold-
ing of either normal or fibrotic liver. These include collagens, non-collagen glycoproteins, 
matrix-bound growth factors, glycosaminoglycans, proteoglycans and matricellular proteins. 
In case of fibrosis, the total collagen content increases 3- to 10-fold including an increase in 
fibril-forming collagens (i.e., types I, III and IV) and some non-fibril forming collagens (types 
IV and VI). Glycoproteins (fibronectin; laminin; secreted protein, acidic and rich in cysteine: 
SPARC; osteonectin; tenascin, and von Willebrand factor), proteoglycans and glycosamino-
glycans (perlecan, decorin, aggrecan, lumican, and fibromodulin) also accumulate in cirrhotic 
liver. Particularly notable is the shift from heparan sulphate-containing proteoglycans to 
those containing chondroitin and dermatan sulphates. These processes represent a change in 
the type of ECM in subendothelial space from the normal low-density basement membrane-
like matrix to the interstitial type.
The replacement of the low-density matrix with the interstitial type influences the function 
of hepatocytes, liver stellate cells, and endothelium of blood vessels: the microvilli disappear 
on the surface of liver parenchymal cells, and endothelium loses fenestrations precluding 
effective molecule exchange between blood and liver parenchyma. In addition, stellate cells 
undergo activation [23].
The hepatic stellate cell is the primary source of ECM in normal and fibrotic liver. Hepatic 
stellate cells, located in subendothelial space of Disse between hepatocytes and sinusoidal 
endothelial cells, represent one-third of the non-parenchymal population or approximately 
15% of the total number of resident cells in normal liver. Stellate cells comprise a heteroge-
neous group of cells that are functionally and anatomically similar but differ in their expres-
sion of cytoskeletal filaments, retinoid content, and potential for activation. Stellate cells 
with fibrogenic potential are not confined to liver and have been identified in other organs 
such as the pancreas, where they contribute to desmoplasia in chronic pancreatitis and car-
cinoma. Hepatic stellate cell activation is the common pathway leading to hepatic fibrosis. 
During activation, stellate cells undergo a transition from a quiescent vitamin A-rich cell into 
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 proliferating, fibrogenic, and contractile myofibroblasts [23], which have strong ability to 
secrete collagen and migrate to the area of necrosis and inflammation [40]. Proliferation of 
stellate cells occurs predominantly in regions of greatest injury.
Considering liver fibrosis, the balance between synthesis and degradation of extracellular 
matrix also is of importance as enhanced destruction of the normal matrix in the space between 
hepatocytes and endothelial cells leads to accumulation of dense scar tissue. Degradation 
occurs through the actions of at least four enzymes: matrix metalloproteinase (MMP) 2 and 
MMP9, which degrade type IV collagen; membrane-type metalloproteinase 1 or 2, which acti-
vate latent MMP2 and stromelysin 1, which degrades proteoglycans and glycoproteins and 
activates latent collagenases. Stellate cells are the principal source of MMP2 and stromelysin. 
Activation of latent MMP2 may require interaction with hepatocytes. Markedly increased 
expression of MMP2 is a characteristic of cirrhosis. MMP9 is secreted locally by Kupffer cells. 
Disruption of the normal liver matrix is also a prerequisite for tumour invasion and stromal 
desmoplasia.
The cytochrome CYP2E1 may have an important role in the generation of reactive oxygen 
species that stimulate liver stellate cells. Cultured hepatic stellate cells grown in the pres-
ence of CYP2E1-expressing cells increase the production of collagen, an effect prevented by 
antioxidants or a CYP2E1 inhibitor. These data suggest that the CYP2E1-derived reactive oxy-
gen species are responsible for the increased collagen production. Such findings may help 
to explain the pathogenesis of liver injury in alcoholic liver disease since CYP2E1 is alcohol 
inducible. As noted above, reactive oxygen species are generated through lipid peroxidation 
from hepatocytes, macrophages, stellate cells, and inflammatory cells. In alcoholic or non-
alcoholic steatohepatitis, ROS generation in hepatocytes results from induction of cytochrome 
P450 2E1, leading to pericentral (zone 3) injury. Also, oxidase of the reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) mediates fibrogenic activation of hepatic stellate 
cells, as well as of Kupffer cells or resident liver macrophages through generation of oxidative 
stress. Increasing knowledge about NADPH oxidase isoforms and their cell-specific activities 
is leading to their emergence as a therapeutic target [23].
Pathology of telomeres and the related molecular events represent another key mechanism 
that is associated both with induction of liver steatosis and progression of NAFLD [41]. 
Telomerase mutations can accelerate progression of chronic liver disease to cirrhosis [42]. 
Missense mutations in telomerase reverse transcriptase hTERT are found more frequently in 
cirrhosis regardless of aetiology [41]. Thus, missense mutations were observed in 7% of cir-
rhotic patients in USA [43]. Functional mutations were identified in 3% of German patients 
affected by cirrhosis [44].
Telomeres are repeated, short DNA sequences (in humans—TTAGGG) located at the chromo-
some end. These structures prevent chromosomal end-to-end fusion as well as protect the cod-
ing DNA from progressive loss at mitosis. During each mitosis, the DNA polymerase complex 
cannot replicate the terminal 5′ end of the lagging strand. Consequently, the chromosomal end 
is lost. Due to the presence of telomeres, this loss is limited to telomeres. However, the telo-
meres shorten in each mitosis. Telomere attrition is especially marked in chronic diseases asso-
ciated with increased cell loss and proliferation. When they become critically short,  cellular 
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ageing s. senescence and apoptosis follows. To ensure the unlimited proliferation of cancer, 
malignant cells maintain telomere length via different mechanisms. The most significant ones 
include telomerase reverse transcriptase hTERT, its RNA template: telomerase RNA com-
ponent hTERC, the hTERC-protecting and stabilising dyskerin complex (consisting of four 
nucleolar proteins) and shelterin complex, including six proteins [41].
NAFLD is characterised by telomere shortening and increased cellular senescence in com-
parison to healthy controls [45]. The changes in telomeres represent an important mechanism 
in the transition to liver cirrhosis. However, dual effects are observed. In progressing chronic 
liver disease, cellular senescence enhances the loss of parenchyma, limiting the replicative 
potential of hepatocytes. In contrast, in advanced liver damage, the ageing of stellate cells 
stops the remodelling and thus, the further progression of fibrosis. Still another prognos-
tic aspect can be involved regarding HCC development: senescent stellate cells can promote 
carcinogenesis by secreting pro-carcinogenic mediators. These changes are described as the 
senescence-associated secretory program [41]. The extent of fibrosis in NAFLD is associated 
with p21 protein representing another molecular regulator of cellular senescence [41].
Although shorter telomeres are considered a hallmark of liver cirrhosis regardless of aeti-
ology [41], the telomeres in NAFLD patients are shorter than in those affected by crypto-
genic cirrhosis. In NAFLD, telomere length correlates with the level of hTERT mRNA, while 
hTERT-independent mechanisms already start to operate in cryptogenic cirrhosis [45].
4. NASH-induced HCC
Although the association between NAFLD and HCC was first observed more than two decades 
ago, mostly through NASH-induced cirrhosis [11], the molecular events that link NAFLD and 
HCC are still incompletely understood. Following the general principles of cancerogenesis, 
HCC in cirrhotic liver develops by dysplasia—carcinoma pathway: from a dysplastic cirrhotic 
nodule. The process is slow and can last for several decades [34]. The genetic events that are 
prerequisite for malignant change develop in the background of increased cellular prolif-
eration. Hypothetically, it is possible that the molecular portrait of HCC in DNA, mRNA, 
microRNA and protein level is different in accordance to the inciting factor of the underlying 
liver disease. If this is true, specific molecular targets may exist for the diagnostics, prevention 
or treatment of NASH-induced HCC or HCC arising in diabetic and/or obese patients [10].
The course of HCC that is associated with cryptogenic cirrhosis differs from HCC develop-
ing in other clinical settings [46]. HCC also varies by epigenetic signature in accordance to 
the cause [47].
The risk of hepatocellular carcinoma differs by the aetiology of cirrhosis. To estimate this, a 
large population-based study was carried out in the United Kingdom. All patients diagnosed 
with liver cirrhosis were identified, and the results were compared to national cancer regis-
try identifying those diagnosed with HCC. The 10-year cumulative incidence of HCC was 
4% in cirrhosis induced by chronic viral hepatitis, 3.2% in cirrhosis due to autoimmune or 
metabolic (in this study—haemochromatosis, alpha-1-antitrypsin deficiency) diseases, 1.2% 
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in alcohol-induced cirrhosis and 1.1% in cryptogenic cirrhosis, while the same estimates at 1 
year were 1.0, 0.8, 0.3 and 0.3%, respectively. This study has the significant benefit of explor-
ing HCC risk in patients that differ by aetiology of cirrhosis but belong to the same popula-
tion [37]. Considering patients referred for liver transplantation, the frequency of hepatocellular 
carcinoma in cryptogenic cirrhosis is lower (8%) than in cirrhosis related to chronic hepatitis B 
(29%) or C (19%) as reported by Alamo et al. [32]. For the epidemiological estimates of HCC in 
different liver pathology, see also Table 2 [37, 38].
The causal distribution of HCC shows geographic variations. Thus, in Canadian patients, 45% of 
cases were attributable to alcohol-induced cirrhosis, 26% to cryptogenic cirrhosis and 13% to hep-
atitis C. In patients from Saudi Arabia, 47% of HCC were caused by hepatitis C, 27% by cryptogenic 
cirrhosis and 21% to hepatitis B [48]. In USA, regarding the HCC cause, 54.9% of cases were 
induced by HCV, 16.4% by alcohol, 14.1% by NAFLD and 9.5% by HBV [10]. In explanted livers, 
81.8% of HCC were associated with viral hepatitis, 9.1% with alcohol-induced liver damage and 
9.1% with NAFLD [36]. 
In the USA, the number of NAFLD-associated HCC cases is annually growing for 9%, if the 
time span 2004–2009 is evaluated [10]. In Europe, NAFLD-related HCC comprised 35% of all 
HCC cases in 2010. HCC that is not related to hepatitis B or C is becoming increasingly fre-
quent in Japan as well; however, here, it comprises only 10% of all HCC cases [53]. NASH is 
responsible for higher percentage of HCC in Western than in Eastern societies [12].
Hepatocellular carcinoma in patients affected by metabolic syndrome has distinct morphology 
[49]. NAFLD-associated HCC is characterised by larger size [34] and moderate or high differen-
tiation degree [34], showing high differentiation as frequently as in 65% of cases [49]. However, 
the tumours lack capsule thus confirming the true malignant biological potential [34]. This is an 
important diagnostic trait considering the association between NAFLD, low-grade HCC [49], 
and liver adenomatosis [50].
The prognostic estimates are somewhat controversial. The NAFLD-associated hepatocellular 
carcinomas are diagnosed as more advanced tumours in older patients showing higher car-





Chronic hepatitis Cryptogenic 
cirrhosis
Reference
SIR; 95% CI 70.6; 59.5–83.2 47.0;1 12.6–120.2 42.7;2 25.2–67.3 43.4; 30.3–60.4 Sorensen et al. 
[38]
Incidence rate 
per 1000 person 
years; 95% CI
3.2; 2.1–4.8 5.3; 2.6–10.5 7.6;3 4.3–13.4 3.1; 1.6–5.9 West et al. [37]
Abbreviations: SIR, standardised incidence ratio; CI, confidence interval.
1Primary biliary cirrhosis.
2Including viral and autoimmune causes.
3Viral hepatitis.
Table 2. Epidemiological estimates of hepatocellular carcinoma by the cause of chronic advanced liver pathology.
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tumour-specific mortality [10]. HCC associated with cryptogenic cirrhosis is larger than can-
cers related to HCV even in patients who correspond to Milan criteria [51]. However, after 
curative treatment, the recurrence risk and mortality are lower for HCC arising in cryptogenic 
cirrhosis—finding that is in accordance with the grade difference [52].
Although previously it was considered that HCC risk is limited to cirrhotic patients, currently 
at least 25–30% of NAFLD-related hepatocellular carcinomas develop in the absence of cirrho-
sis [9]. In Japanese group, 33% of NAFLD-related HCC occurred in the background of none 
or mild fibrosis contrasting with only 16% in alcohol-induced HCC [53]. According to other 
researchers, up to 65% of NAFLD-associated HCC evolve in the absence of fibrosis [49]. The 
proportion of NAFLD-associated HCC developing in non-cirrhotic liver has been variably 
estimated as 15, 38, or 49% [54–57]. These tumours tend to be larger [57].
The development of HCC in noncirrhotic liver has been associated with malignant transfor-
mation in liver cell adenoma [34, 49]. Malignant change in hepatic adenoma correlates with 
metabolic syndrome [58]. Inflammatory molecular type of liver cell adenoma shows clinical 
correlation with obesity. The underlying molecular basis could include either activated IL-6 
signalling or hyperoestrogenemia associated with obesity. However, a controversy exists here 
as inflammatory type of liver adenoma is not prone to malignisation [50].
Several pathogenetic ways account for a tumour-promoting environment in obesity and dia-
betes, allowing to distinguish the pathogenesis of HCC linked to NAFLD from that of viral 
and other aetiologies.
Obesity has been linked to higher frequency of cancers in a variety of tissues [59, 60] including 
the liver (Table 3). HCC is increasingly diagnosed among obese individuals. In a prospec-
tive cohort of the Cancer Prevention Study with more than 900,000 North American subjects, 
the relative risk of dying from liver cancer among men with a body mass index reaching or 
exceeding 35 kg/m2 was remarkably higher (4.5 fold) compared to a reference group with nor-
mal body weight. In a large cohort involving 362,552 Swedish men, the relative risk of HCC in 
individuals with a body mass index reaching or exceeding 30 kg/m2 was 3.1 fold higher than 
in controls having normal weight. Studies from other parts of the world indicate that the link 
between obesity and increased incidence of HCC has been globally recognised [61].
Obesity has a significant tumour-promoting effect regarding HCC. This effect largely 
depends on the chronic general low-grade inflammatory response it induces, which involves 
production of TNF-α and IL-6. Both these molecular mediators are tumour-promoting cyto-
kines [62] and major drivers of cell proliferation in NAFLD and NASH [21]. TNF-α and other 
mediators produced by activated inflammatory macrophages stimulate compensatory hepa-
tocyte proliferation and expand HCC progenitors. TNF-α further reinforces the inflammatory 
microenvironment and induces expression of chemokines (CCL2, CCL7 and CXCL13) and 
growth factors/cytokines (IL-1β, IL-6, TNF–α itself and hepatocyte growth factor) both by 
progenitors of hepatocellular carcinoma and surrounding cells [63]. TNF-α up-regulates the 
cellular proliferation through the molecular pathways of nuclear factor kappaB, mTOR and 
wide spectrum of kinases. The proliferative and anti-apoptotic activities of IL-6 are largely 
mediated through the signal transducer and activator of transcription 3, STAT3 [10]. IL-6 also 
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contributes to the metabolic background of cancer sustaining insulin resistance that can be 
improved by systemic neutralization of IL-6 [64].
Another mechanism involved in the progression of NAFLD to HCC in obese individuals is 
the imbalance between leptin and adiponectin. Particularly, obesity is linked to increased 
levels of leptin [34]. Apart from its role in obesity-associated insulin resistance and inflam-
mation, leptin is a pro-inflammatory, pro-angiogenic, and pro-fibrogenic cytokine with a 
growth-promoting effect by activating the Janus kinase/STAT, phosphoinositide 3-kinase 
(PI3K)/Akt, and extracellular signal-regulated kinase (ERK) signalling pathways [61]. The 
up-regulation of PI3K/Akt pathway leads to activation of downstream molecular mediator 
mTOR that is found in 40% of HCC cases. Leptin-induced up-regulation of mTOR also inhib-
its autophagy—a process that normally would limit oxidative stress by removing damaged 
mitochondria. Suppression of autophagy, in turn, increases oxidative tissue damage and sub-
sequent inflammation [21]. Since leptin exerts pro-inflammatory and pro-fibrogenic effects 
by activating Kupffer cells and stellate cells, it has been associated to disease progression in 
fibrotic NAFLD [10]. Leptin can also promote invasion and migration of hepatocellular car-
cinoma cells [65].
Adiponectin, another major adipokine with potent anti-inflammatory, antiangiogenic and 
tumour growth-limiting properties, is suppressed in obesity [15, 24]. Adiponectin activates 
5′-adenosine monophosphate–activated protein kinase, which can suppress tumour growth and 
increase apoptosis by regulating the mTOR and c-Jun N-terminal kinase/caspase 3 pathways. 
Moreover, adiponectin opposes the effects of leptin by inhibiting activation of Akt and STAT3, 
as well as by increasing the expression of SOCS3: the suppressor of cytokine signalling 3 [61]. 
Location Level of evidence
Oesophageal adenocarcinoma Strong






Liver cancer Highly suggestive




Melanoma in males Weak
Table 3. Obesity-related human cancers [60].
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Thus, low adiponectin levels may be insufficient to suppress endotoxin-mediated inflammatory 
signalling in Kupffer cells and other macrophages, as well as control angiogenesis, a pivotal 
mechanism of tumour growth [10]. Microarray analysis of tissue adiponectin levels in HCC 
patients revealed that adiponectin expression was inversely correlated with tumour size, sup-
porting the hypothesis that adiponectin may inhibit proliferation and dedifferentiation [66].
HCC can show marked accumulation of fat within the neoplastic cells (Figure 4). In a 
study by Salomao et al., 36% of patients who developed HCC in the setting of steatohepa-
titis were diagnosed as having a steatohepatitic variant of HCC as compared to 1.3% of 
HCC patients without steatohepatitis [67]. Increased intensity of fatty acid synthesis and 
characteristic pattern of perilipin proteins has been demonstrated in HCC. Regarding gene 
expression pattern, activated lipogenesis is associated with higher cell proliferation and 
worse prognosis in HCC [10]. Hypothetically, HCC cells might benefit from the energetic 
value of fat compounds or use lipids as building blocks of new cells.
Lipotoxicity, defined as the cellular dysfunction caused by ectopic deposition of fat in non-
adipose tissues, may contribute to the development of HCC in NAFLD. Activated oxidation 
of fatty acids generates high burden of free radicals and lipid peroxide compounds that oxi-
dise and damage large molecules and cell organoids, e.g., mitochondria and endoplasmic 
reticulum. The damaged cells are subjected to apoptosis, leading to higher activity in liver 
destruction and progression towards cirrhosis that in turn is closely associated with enhanced 
proliferation and accumulation of genetic damage. Accumulation of fatty acids may interfere 
with cellular signalling and promote oncogenesis through altered regulation of gene tran-
scription [10]. Oxidative stress can induce mutations in the tumour suppressor gene TP53 in 
a pattern observed in HCC [68].
Adipose tissue expansion, release of pro-inflammatory cytokines, and lipotoxicity collectively 
promote systemic and hepatic insulin resistance, resulting in hyperinsulinemia [34]. The risk 
of HCC in patients affected by diabetes mellitus is 2.31 [57]. Insulin resistance and hyperinsu-
linemia are the most common metabolic features of NAFLD, which correlate with impaired 
hepatic clearance of insulin and have been linked to tumour development [69]. Deregulated 
metabolic effects of insulin result in excessive activation of proliferative signalling cascades. 
Figure 4. Hepatocellular carcinoma showing nuclear atypia and presence of fat in tumour cells. Haematoxylin-eosin 
stain, original magnification 100× and 400×.
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Hyperinsulinemia causes reduced hepatic synthesis of insulin-like growth factor (IGF)-
binding protein-1 and increased bioavailability of IGF1, which further promotes cellular 
proliferation and inhibits apoptosis [10, 34]. It has been shown recently that elevated fasting 
insulin, which is inversely related to insulin sensitivity, is an independent risk factor for HCC. 
Baseline serum levels of C-peptide have also been found to be associated with a higher risk 
of HCC in the general population independently of obesity and other established liver cancer 
risk factors [69]. Loss of heterozygosity for IGF2 has been observed in over 60% of HCC cases. 
This likely coincides with IGF2 overexpression, found in HCC, which has been associated to 
reduced apoptosis and increased cellular proliferation [68].
The importance of insulin resistance is illustrated by the observations that obesity and type 
2 diabetes mellitus comprise increased HCC risk even regardless of the presence or cause of 
liver cirrhosis [9].
A number of studies have demonstrated a critical role for phosphatase and tensin homolog 
(PTEN) in the progression of NASH to tumour. PTEN deletion results in PKB/Akt activation, 
promoting proliferation and reducing apoptosis. Insulin-like growth factor 2 mRNA binding 
protein p62 was reported to be a possible upstream regulator of PTEN. Aberrant microRNAs 
contribute to carcinogenesis. MiR-21 was found to be another upstream regulator of PTEN 
participating in NASH-associated cancer induction [10, 14, 70].
The oral iron test has revealed increased absorption of iron compounds in patients affected by 
NASH [71]. In turn, increased amount of iron in liver tissues is associated with increased risk 
of HCC in patients affected by NASH-related liver cirrhosis [72]. As the reductive conversion 
of Fe(III) to Fe(II) necessitates increased oxidation of other compounds, oxidative DNA dam-
age can develop and lead to the malignancy [34, 73]. Iron overload also is known to enhance 
insulin resistance [74] and to act in concert with other factors damaging liver. The significance 
of iron overload in hepatic carcinogenesis is shown in several models. The risk of HCC is 
increased in hereditary haemochromatosis, characterised by excessive iron accumulation in 
the body and caused by excessive absorption because of homozygous C282Y mutation in HFE 
gene. Almost 8–10% of patients with hereditary haemochromatosis develop HCC. Increased 
relative risk of HCC (10×) has also been demonstrated in association with long-lasting excess 
dietary iron intake [37, 74, 75]. Thus, there is significant evidence of the carcinogenic action 
of iron overload, and evidence of iron accumulation in NAFLD and especially NASH that 
allows drawing conclusion that iron metabolites are contributing to the development of 
NASH-related HCC.
The expression profile of Wnt signalling genes in NASH strongly suggests inhibition of 
Wnt pathway. IHC staining of β-catenin shows predominately membrane staining with loss 
of nuclear staining indicating that β-catenin is not active in NASH. In contrast, 20–90% of 
HCC cases exhibit active Wnt pathway [76]. Thus, the long-lasting conversion of NASH into 
HCC hypothetically involves up-regulation of Wnt pathway either by activators or loss of 
inhibitors [77].
Hepatocyte apoptosis is a prominent feature of NASH (Figure 5). The executing mechanism 
of apoptosis includes activation of characteristic lytic enzymes—the caspases. In an apoptotic 
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hepatocyte, activated caspase-3 is splitting various cell structures, including cytokeratin (CK) 
18—the intermediary filament that represents the specific cytoskeleton protein of hepatocytes. 
Consequently, blood tests can reveal increased concentration of CK18 fragments [70]. In liver tis-
sues, CK8 and CK18-containing Mallory bodies are evident by light microscopy as large, brightly 
eosinophilic inclusions in liver cell cytoplasm. Although Mallory hyaline is the hallmark of alco-
hol-induced hepatitis, its development can also be induced by diet rich in saturated fatty acids. 
The molecular pathways associated with Mallory body development include IL-6, protein p62 
that binds ubiquitin in cell cytoplasm, and reduced concentration of HSP72 that prevents protein 
misfolding. The presence of CK18 in Mallory bodies correlates with plasma CK18 levels [78]. In a 
longitudinal paired liver biopsy study, the change of CK18 correlated with disease progression. 
Patients with increased NAFLD activity score 3 years after initial evaluation had greater increase 
of plasma CK18 compared with those who had stable or decreased activity score [79]. El-Zefzafy 
et al. proved that CK18 was a sensitive indicator of the severity of liver disease and also could 
predict the development of HCC. In their study, the sensitivity and specificity of serum CK18 
were 95 and 96.7%, respectively, with a cut-off value of 534.5 U/L for HCC diagnosis [80].
In a study by Salomao et al., devoted to HCC in NASH, immunohistochemically there was 
diffuse loss of cytoplasmic CK8/18 and an increased number of activated hepatic stellate cells 
within the steatohepatitic HCC, identical to the pattern seen in the surrounding non-neoplastic 
liver [67, 81].
Figure 5. Apoptotic bodies (arrows) in non-alcoholic steatohepatitis. Haematoxylin-eosin stain, original magnification 
400×.
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The HCC development shows complex associations with telomere shortening. The senes-
cence-associated secretory program of liver stellate cells promotes carcinogenesis. The telo-
mere shortening induces also genomic instability thus facilitating HCC development [41]. 
Indeed, HCC is characterised by significantly shorter telomeres in comparison to adjacent 
tissues [82]. However, cancer cells still maintain unlimited proliferation. Evidently, hepatocel-
lular carcinoma cells develop compensatory mechanisms either for telomere extension or for 
cellular proliferation despite telomere shortening. The elongation of telomeres again can be 
ensured via diverse mechanisms, including hTERT or alternative lengthening of telomeres via 
telomerase-independent mechanism seen in 7% of HCC cases [41].
Over the progression of HCC, the telomere length changes in contrary direction. Early liver car-
cinogenesis is associated with telomere shortening, while disease progression is associated with 
telomere extension, cell immortalisation and reactivation of telomerase [83]. Longer telomeres 
in HCC are associated with higher stage (regional or distant spread versus localised tumour) and 
grade (III–IV versus lower grade) as well as with worse survival [83, 84]. Telomerase promotes 
HCC development via several pathways, not limited to maintenance of telomeres and thus 
cellular proliferation. In addition, hTERT can act as a transcription factor in the Wnt molecular 
cascade [41]. Experimental data by HCC induction in telomerase-deficient mice have shown 
increased number of early tumours and reduced incidence of high-grade HCC [85].
Interestingly, shorter telomeres are observed more frequently (telomere length ratio between 
HCC and surrounding tissues lower than the mean, 70.1% versus higher, 29.9%) in HCC that is 
not related to hepatitis B (50.0% versus 50.0%) or C (60.0% versus 40.0%), or alcohol abuse (50.0% 
versus 50.0%), although the difference does not reach statistical significance [83]. Telomere 
shortening can be detected in peripheral blood. Notably, this assay can be used to predict 
HCC persistence (by telomere shortening) in cases attributable to viral hepatitis B or C but not 
in HCC attributable to non-infectious causes despite comparable size of patient groups [86].
Genetic predisposition has been studied in NAFLD trying to identify those patients that 
are at particularly increased risk of HCC. The possible candidate genes could be associated 
with telomere length and mechanisms involved in preserving telomeres [42]. About 10% of 
patients affected both by HCC and NASH have germline mutations in hTERT in comparison 
to complete absence of such mutations in NASH patients having cirrhosis and healthy con-
trols [41]. In addition, PNPLA3 polymorphisms have been studied in NAFLD patients, find-
ing twice increased risk of HCC in association with rs738409 C>G. The proposed mechanism 
involves retinol metabolism in hepatic stellate cells [34].
The interaction of these pathogenetic mechanisms and genetic predisposition finally results 
in the increased incidence of HCC in NAFLD that reaches 76–201 per 100,000 contrasting 
with the incidence of 4.9–16 per 100,000 of the general population [57].
5. Potential treatment strategies
As no specific treatment is approved for NAFLD, lifestyle interventions play the leading role 
in NAFLD management. Weight loss due to low calorie diet in combination with physical 
activities is the main therapeutic approach in overweight patients with NAFLD. As hypertri-
glyceridemia is a frequent and promoting feature of NAFLD [87] reduction of the triglyceride 
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level must be among therapeutic goals. In severe hypertriglyceridemia, total fat consumption 
should be limited to less than 30 g/day, and carbohydrate amount in daily nutrition should be 
strictly controlled as well [88].
Physical activity has beneficial effect of reducing triglyceride level, even independently 
from diet [89]. Thus, at least 30 min of moderate activity most days of the week would be 
a necessary part of dyslipidemia management [90]. Loss of 5% of body weight decreases 
hepatic steatosis, but body weight loss of 10% could even improve inflammation and fibro-
sis in liver [87].
Experimentally investigating hepatocyte-specific PTEN-deficient mouse model, Piguet et 
al. showed that physical activity could reduce HCC growth in fatty liver. In PTEN-deficient 
mice, HCC incidence was 71% of exercised mice and 100% of sedentary mice. In addition, 
liver tumour volume in exercised mice was significantly smaller than that of sedentary mice 
(444 ± 551 versus 945 ± 1007 mm3) [91]. The physiological substantiation relies on fact that 
regular physical activity could inhibit mTOR complex, which is engaged in cell growth and 
proliferation [92].
Increased hepatic free cholesterol accumulation is typical for NASH. Statins are commonly 
prescribed to reduce cholesterol synthesis in the liver and thus serum levels of free cholesterol 
[14]. In a recent European multi-centre cohort study, statin use was associated with protection 
from steatosis (odds ratio, OR 0.09; 95% CI, 0.01–0.32; p = 0.004), steatohepatitis (OR, 0.25; 95% 
CI, 0.13–0.47; p <0.001), and fibrosis stage F2–F4 (OR, 0.42; 95% CI, 0.20–0.80; p = 0.017). The 
protective effect of statins on steatohepatitis was stronger in subjects not carrying the I148M 
PNPLA3 risk variant (p = 0.02), indicating the role of genetic predisposition [93]. Statins also 
have been associated with reduced risk (range, 0.46–0.79) of HCC [94].
In a meta-analysis, including 4298 patients with HCC, statin use was associated with a 37% 
reduction in the risk of hepatocellular carcinoma. The effect was stronger in Asian patients but 
was also present in Western populations. Moreover, the reduction of cancer risk was indepen-
dent of statin lipid-lowering effects [95]. Several hypotheses have been proposed, including 
statin ability to inhibit cell proliferation via inhibition of v-myc avian myelocytomatosis viral 
oncogene homolog protein phosphorylation which seems to play a role in liver carcinogen-
esis [96], as well as capacity to inhibit the 3-hydroxy-3-methylglutaryl coenzyme A reductase, 
which activates multiple proliferative pathways [95]. Simvastatin selectively induces apopto-
sis in cancer, but not in healthy cells. This proapoptotic effect is maintained via RAF/MAPK1/
ERK and growth-inhibitory action by suppression of angiogenesis and proteasome pathway 
[95, 96]. However, data about liver carcinogenesis and statin effects remain controversial. In 
another large meta-analysis, including 86,936 participants, no beneficial effect of statin in 
terms of incidence or death from cancer was observed. Even more, in 67,258 patients who 
received statins, 35 new liver cancers and 24 deaths from liver cancer were reported show-
ing no significant difference from control group, comprising 67,279 patients who received 
placebo, and developed 33 new liver cancer (p = 0.93) cases leading to 24 deaths (p = 1.00) as 
analysed by Carrat [97].
Metformin, a widely prescribed drug for treating type 2 diabetes mellitus, is one of the most 
extensively recognised metabolic modulators which decreases aminotransferase levels and 
hepatic insulin resistance. It has no beneficial effects on NAFLD histology but still retains an 
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important anti-cancer action [87, 98]. The hypothetic antitumor mechanisms of metformin are 
believed to be (1) inhibition of mTOR, (2) weight loss and (3) suppressed production of ROS 
and the associated DNA damage, in combination with (4) reduction of hyperinsulinemia, 
which is known to lead to cell proliferation [99]. In meta-analysis comprising 105,495 patients 
with type 2 diabetes, Zhang et al. showed that metformin was associated with an estimated 
70% reduction in the risk of developing HCC [98]. The risk reduction in metformin users is 
significant, regarding both incidence (78%) and mortality (77%) from HCC [100].
The mammalian target of rapamycin (mTOR) promotes growth in a majority of liver can-
cers, including hepatocellular carcinoma. It participates in the formation of two protein 
complexes—mTORC1 and mTORC2. mTORC1 is sensitive to rapamycin and has ability to 
activate downstream targets which regulate cellular growth and metabolism. Prolonged 
mTORC1 activation is related to liver steatosis and insulin resistance in obese patients 
[14, 101]. Due to the ability suppress mTORC1, rapamycin and its analogues Everolimus 
and Temsirolimus have been tested to treat HCC. Unfortunately, results have not been 
promising. In a phase 3 study of patients with advanced HCC, Everolimus increased the 
frequency of hepatic injury and showed no improvements regarding survival [14]. After 2 
weeks with rapamycin treatment, the lipid droplets in the liver decreased, as well as ROS 
burden. However, rapamycin treatment promoted liver damage with augmented IL-6 and 
decreased anti-inflammatory IL-10 production, leading to increased hepatic inflammation 
and hepatocyte necrosis [101].
Inflammation promotes development of complications in patients with cirrhosis contributing 
to mortality and to liver insufficiency mediated by pro-inflammatory cytokines. The most 
recognisable pro-inflammatory cytokine associated with liver damage in case of NAFLD is 
TNF-α that can be inhibited by pentoxifylline. Lebrec et al. performed randomised, placebo 
controlled, double-blind trial assessing pentoxifyline effect in 335 patients with cirrhosis. 
Although pentoxifylline had no effect on short-term mortality, it significantly (p = 0.04) pro-
longed the complication-free time span [102].
Knowing the important role of NADPH oxidases (NOXs) and production of ROS in liver fibro-
sis, different strategies to prevent the oxidative damage have been developed [23]. In hepa-
tocytes, NOX4 mediates suppressor effects on TGF-β and can inhibit hepatocyte growth and 
liver carcinogenesis. In turn, dual NOX4/NOX1 pharmacological inhibitor GKT137831 could 
decrease both the apparition of fibrogenic markers as well as hepatocyte apoptosis in vivo [103].
Currently, multikinase inhibitor sorafenib is the only pharmacological agent that prolongs 
survival of HCC patients, although the median survival is improved only by 12 weeks [14]. It 
acts against Raf-1 and B-raf, vascular endothelial growth factor (VEGF) receptors and plate-
let-derived growth factor receptor kinases [104]. Sorafenib as well as VEGF inhibitors have 
radiosensitizing effect. However, combined regimens including sorafenib and liver stereotac-
tic radiation or whole liver radiotherapy are characterized by poor tolerability [104]. Various 
beneficial effects of sorafenib have been reported in liver cirrhosis. As epithelial-mesenchymal 
transition and TGF-β play crucial roles in liver fibrosis, Ma et al. proved that sorafenib had 
ability to strikingly suppress TGF-β1 induced epithelial-mesenchymal transition, as well as 
apoptosis in hepatic stellate cells, in dose-dependent manner [105].
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Several treatment strategies might involve the telomere and telomerase complex. In cancer, 
telomerase inhibitors might arrest tumour growth, prevent further malignisation in surrounding 
cirrhotic nodules and/or enhance HCC chemosensitivity. In early liver disease, telomerase acti-
vation might prevent tissue loss if the etiologic factor cannot be removed. This could be reached 
via transplantation of liver cells engineered for hTERT expression, direct supply of hTERT to the 
patient’s cells or by small molecules enhancing telomerase activity. However, side effects and 
enhanced cancer risk must be considered and prevented [41]. The treatment modulating cellular 
senescence and proliferation control may also target p21 [106–108] and p53 [109] pathways.
The p21 protein, a strong and universal inhibitor of cyclin-dependant kinases, is an impor-
tant regulator of cell proliferation, apoptosis and senescence [107, 108]. Based on its intra-
cellular location and the molecular background, it can have dual activity. Intranuclear 
p21 acts as tumour suppressor, as it binds cyclin-dependant kinases and thus suppresses 
cellular proliferation. Cytoplasmic p21 prevents apoptosis by binding caspases and pro-
motes proliferation and migration of p53-deficient cells. The p21 pathway is also closely 
associated with senescence. Few small molecular inhibitors of p21 are known, including 
LLW10, butyrolactone and UC2288. In addition, sorafenib also exhibits anti-p21 activity. 
LLW10 binds to p21 and induces proteosomal degradation via ubiquitination. Despite the 
reliable mechanism, the high concentration that is necessary for sufficient activity as well 
as the instability of LLW10 prevents it from being clinically useful drug. Butyrolactone 
also induces proteosomal degradation of p21. UC2288 decreases p21 concentration via 
suppressed transcription and modified posttranscriptional modulation [107]. In turn, up-
regulation of p21 can be achieved via statins or by anticancer agents including histone 
deacetylase inhibitors [106]. Induction of senescence would be desirable if the tumour is 
already present while suppressed senescence might prevent or slow down the develop-
ment of liver cirrhosis. As was noted, it is possible to modulate p21 level in both directions. 
However, the net effects must be carefully considered and studied experimentally, know-
ing the bidirectional activity of p21.
p21 is also an effector of p53-mediated responses in cells maintaining functional p53. In 
p53-deficient cell, it manifests carcinogenic effects. Thus, restoration of wild-type p53 
could be attractive, either in combination with p21-targeted treatment or with other onco-
logical approach. In liver cancer, restoration of p53 activity has resulted in senescence 
and increased immune response. The therapeutic approaches could include (1) restora-
tion of wild type function to mutant p53 by low molecular weight compounds PRIMA 1 
or PRIMA-1MET. The last one has progressed to phase II clinical trials; (2) stabilising p53 
due to blocked interaction with MDM2 or MDM4 by nutlins, representing low molecular 
weight molecules, or by stapled peptides; (3) gene therapy using viral vectors that has 
already been tested in HCC; (4) induction of synthetic lethality [109].
6. Conclusions
Non-alcoholic steatohepatitis is recognised as the cause of NASH-induced cirrhosis. It has 
also been associated with a significant fraction of cases previously diagnosed as cryptogenic 
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cirrhosis. Liver cirrhosis can become further complicated by hepatocellular carcinoma, the 
most frequent primary liver tumour known for serious prognosis and limited treatment 
options. In addition, the development of HCC in NAFLD patients can precede cirrhosis in a 
significant fraction of cases. NAFLD is the major hepatic manifestation of obesity and associ-
ated metabolic diseases, such as diabetes mellitus. With increasing prevalence of these condi-
tions, NAFLD has become the most common liver disorder worldwide. It affects around 25% 
of general population and 90% of patients suffering from morbid obesity, i.e., having body 
mass index equal or greater than 40 kg/m2.
The mechanisms of liver steatosis include up-regulation of inflammatory cytokines, as TNF-α, 
IL-6 and CCL2, released from extrahepatic adipose tissues due to prolonged low-grade 
inflammation triggered by hypoxia-induced death of fast-growing fat cells. Insulin resis-
tance further contributes to NAFLD and can be aggravated by the pro-inflammatory cytokine 
background. Free fatty acids and cholesterol cause lipotoxicity due to released reactive oxy-
gen species as well as toxic metabolites generated by non-oxidative biochemical pathways. 
Decreased level of adiponectin, exaggerated oxidative stress and hepatic iron accumulation 
also are among the mechanisms of NAFLD.
In the pathogenesis of NAFLD, 20–30% of patients, initially affected by simple liver steatosis, 
develop hepatic inflammation and thus correspond to the diagnostic criteria of NASH. These 
cases are at risk to progress to liver cirrhosis and hepatocellular carcinoma. The standardised 
incidence ratio of HCC in NASH patients reaches 4.4. Regarding the epidemiological pro-
file of hepatocellular carcinoma, the proportion of NASH-related cases is growing and has 
increased from 8.3 to 13.5% in the time period 2002–2012.
Obesity has been linked to higher frequency of cancers in different organs including the 
liver. The relative risk of HCC-attributable death in obese patients (body mass index equal 
or greater than 35 kg/m2) can be as high as 4.5. The underlying mechanisms of carcinogenesis 
include chronic general low-grade inflammation characterised by elevated levels of TNF-α 
and IL-6, both of which are tumour-promoting cytokines and major drivers of cell prolif-
eration in NAFLD and NASH. The increased levels of leptin and suppressed production of 
adiponectin represent another mechanism involved in the progression of NAFLD to HCC 
in obese individuals. Leptin is a pro-inflammatory, pro-angiogenic and pro-fibrogenic cyto-
kine with a growth-promoting effect. Adiponectin has anti-inflammatory, antiangiogenic and 
tumour growth-limiting properties. Insulin resistance and hyperinsulinemia lead to excessive 
cell proliferation. Iron compound deposition has also been related to HCC development in 
NAFLD-related cirrhosis, possibly due to oxidative DNA damage. Thus, the same molecular 
pathways that induced NAFLD continue to be active until the development of HCC. These 
mechanisms are supplemented by critical genetic events including PTEN deletion, switch 
from inactivated to upregulated Wnt pathway and typical mutation pattern in TP53. Certain 
microRNAs, including miR-21, act as molecular switches.
Pathogenetically related molecular markers, e.g., cytokeratin 18, can serve as predictive tests 
to detect increased risk of HCC.
The molecular pathogenesis of NAFLD is closely related to the selection of treatment tar-
gets. NAFLD patients can benefit from low calorie diet, reducing hypertriglyceridemia and 
potentially reversing steatosis and even fibrosis; physical activity inhibiting mTOR complex; 
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statins influencing cholesterol synthesis, RAF/MAPK1/ERK and p21 pathway; metformin act-
ing through suppression of mTOR and ROS; pentoxyfillin lowering production of pro-inflam-
matory cytokines. Multikinase inhibitor sorafenib is indicated in HCC patients. Bidirectional 
regulation of telomere attrition, senescence, and p21 pathway could be at least theoretically 
considered in the future. Restoration of wild-type p53 activity becomes possible. The regula-
tion of miRNA machinery also represents a highly attractive future treatment option.
Thus, NAFLD is gaining increasing importance in nowadays medicine as a frequent condi-
tion that can lead to such grave complications as liver cirrhosis and hepatocellular carcinoma. 
Awareness of the molecular profile is helpful to identify the treatment targets and predictive 
markers.
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